Cargando…

Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study

PURPOSE: MET is a notable driver gene in the diversity of aberrations with clinical relevance, including exon 14 skipping, copy number gain, point mutations, and gene fusions. Compared with the former two, MET fusions are severely under‐reported, leaving a series of unanswered questions. In this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Hui, Zhang, Junhua, Chen, Tong, Wang, Mingzhao, Chen, Dongna, Si, Tongguo, Liu, Yutao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358190/
https://www.ncbi.nlm.nih.gov/pubmed/37326363
http://dx.doi.org/10.1002/cam4.6047
_version_ 1785075610488406016
author Xia, Hui
Zhang, Junhua
Chen, Tong
Wang, Mingzhao
Chen, Dongna
Si, Tongguo
Liu, Yutao
author_facet Xia, Hui
Zhang, Junhua
Chen, Tong
Wang, Mingzhao
Chen, Dongna
Si, Tongguo
Liu, Yutao
author_sort Xia, Hui
collection PubMed
description PURPOSE: MET is a notable driver gene in the diversity of aberrations with clinical relevance, including exon 14 skipping, copy number gain, point mutations, and gene fusions. Compared with the former two, MET fusions are severely under‐reported, leaving a series of unanswered questions. In this study, we addressed this gap by characterizing MET fusions in a large, real‐world Chinese cancer population. METHODS: We retrospectively included patients with solid tumors who had DNA‐based genome profiles acquired through targeted sequencing from August 2015 to May 2021. MET fusion‐positive (MET+) patients were subsequently selected for clinical and molecular characterization. RESULTS: We screened 79,803 patients across 27 tumor types and detected 155 putative MET fusions from 122 patients, resulting in an overall prevalence of 0.15%. Lung cancer comprised the majority of MET+ patients (92, 75.4%). Prevalence was markedly higher in liver cancer, biliary tract cancer, and renal cancer (range 0.52%–0.60%). It was lower in ovarian cancer (0.06%). A substantial proportion (48/58, 82.8%) of unique partners were reported for the first time. High heterogeneity was observed for partners, with ST7, HLA‐DRB1, and KIF5B as the three most common partners. Mutational landscape analysis of lung adenocarcinoma (n = 32) revealed a high prevalence of TP53 in MET+ alterations, EGFR L858R, EGFR L861Q, and MET amplification. CONCLUSION: To our knowledge, this is currently the largest study in characterizing MET fusions. Our findings warrant that further clinical validation and mechanistic study may translate into therapeutic avenues for MET+ cancer patients.
format Online
Article
Text
id pubmed-10358190
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103581902023-07-21 Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study Xia, Hui Zhang, Junhua Chen, Tong Wang, Mingzhao Chen, Dongna Si, Tongguo Liu, Yutao Cancer Med RESEARCH ARTICLES PURPOSE: MET is a notable driver gene in the diversity of aberrations with clinical relevance, including exon 14 skipping, copy number gain, point mutations, and gene fusions. Compared with the former two, MET fusions are severely under‐reported, leaving a series of unanswered questions. In this study, we addressed this gap by characterizing MET fusions in a large, real‐world Chinese cancer population. METHODS: We retrospectively included patients with solid tumors who had DNA‐based genome profiles acquired through targeted sequencing from August 2015 to May 2021. MET fusion‐positive (MET+) patients were subsequently selected for clinical and molecular characterization. RESULTS: We screened 79,803 patients across 27 tumor types and detected 155 putative MET fusions from 122 patients, resulting in an overall prevalence of 0.15%. Lung cancer comprised the majority of MET+ patients (92, 75.4%). Prevalence was markedly higher in liver cancer, biliary tract cancer, and renal cancer (range 0.52%–0.60%). It was lower in ovarian cancer (0.06%). A substantial proportion (48/58, 82.8%) of unique partners were reported for the first time. High heterogeneity was observed for partners, with ST7, HLA‐DRB1, and KIF5B as the three most common partners. Mutational landscape analysis of lung adenocarcinoma (n = 32) revealed a high prevalence of TP53 in MET+ alterations, EGFR L858R, EGFR L861Q, and MET amplification. CONCLUSION: To our knowledge, this is currently the largest study in characterizing MET fusions. Our findings warrant that further clinical validation and mechanistic study may translate into therapeutic avenues for MET+ cancer patients. John Wiley and Sons Inc. 2023-06-16 /pmc/articles/PMC10358190/ /pubmed/37326363 http://dx.doi.org/10.1002/cam4.6047 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Xia, Hui
Zhang, Junhua
Chen, Tong
Wang, Mingzhao
Chen, Dongna
Si, Tongguo
Liu, Yutao
Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study
title Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study
title_full Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study
title_fullStr Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study
title_full_unstemmed Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study
title_short Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study
title_sort molecular characterization of met fusions from a large real‐world chinese population: a multicenter study
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358190/
https://www.ncbi.nlm.nih.gov/pubmed/37326363
http://dx.doi.org/10.1002/cam4.6047
work_keys_str_mv AT xiahui molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy
AT zhangjunhua molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy
AT chentong molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy
AT wangmingzhao molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy
AT chendongna molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy
AT sitongguo molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy
AT liuyutao molecularcharacterizationofmetfusionsfromalargerealworldchinesepopulationamulticenterstudy